Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Adicet Bio Inc (ACET)

Adicet Bio Inc (ACET)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,687
  • Shares Outstanding, K 82,174
  • Annual Sales, $ 0 K
  • Annual Income, $ -142,660 K
  • 60-Month Beta 1.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.50
Trade ACET with:

Options Overview Details

View History
  • Implied Volatility 128.09% ( -160.79%)
  • Historical Volatility 55.19%
  • IV Percentile 45%
  • IV Rank 20.02%
  • IV High 608.42% on 04/22/24
  • IV Low 7.83% on 09/16/24
  • Put/Call Vol Ratio 0.50
  • Today's Volume 6
  • Volume Avg (30-Day) 48
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 1,194
  • Open Int (30-Day) 1,224

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.34
  • Number of Estimates 4
  • High Estimate -0.27
  • Low Estimate -0.37
  • Prior Year -0.71
  • Growth Rate Est. (year over year) +52.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3200 +7.58%
on 09/25/24
1.6300 -12.88%
on 09/12/24
-0.0900 (-5.96%)
since 09/04/24
3-Month
1.0700 +32.71%
on 07/05/24
1.7000 -16.47%
on 07/29/24
+0.3300 (+30.28%)
since 07/03/24
52-Week
1.0500 +35.24%
on 07/03/24
3.7700 -62.33%
on 01/09/24
+0.1300 (+10.08%)
since 10/04/23

Most Recent Stories

More News
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on April...

ACET : 1.4200 (unch)
Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 1.4200 (unch)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on March...

ACET : 1.4200 (unch)
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights...

ACET : 1.4200 (unch)
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 1.4200 (unch)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on February...

ACET : 1.4200 (unch)
Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 1.4200 (unch)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on January...

ACET : 1.4200 (unch)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on December...

ACET : 1.4200 (unch)
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced positive safety and efficacy data...

ACET : 1.4200 (unch)

Business Summary

Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.

See More

Key Turning Points

3rd Resistance Point 1.4967
2nd Resistance Point 1.4733
1st Resistance Point 1.4467
Last Price 1.4200
1st Support Level 1.3967
2nd Support Level 1.3733
3rd Support Level 1.3467

See More

52-Week High 3.7700
Fibonacci 61.8% 2.7310
Fibonacci 50% 2.4100
Fibonacci 38.2% 2.0890
Last Price 1.4200
52-Week Low 1.0500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar